Comparative Pharmacology
Head-to-head clinical analysis: DUEXIS versus TENATHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUEXIS versus TENATHAN.
DUEXIS vs TENATHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUEXIS is a combination of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and famotidine, a histamine H2-receptor antagonist that decreases gastric acid secretion. Famotidine mitigates the risk of NSAID-induced gastric ulcers.
TENATHAN is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, leading to increased serotonin levels in the synaptic cleft.
One tablet (800 mg ibuprofen/26.6 mg famotidine) orally three times daily.
1 tablet (40 mg) orally once daily, increased to 80 mg once daily if needed after 4 weeks.
None Documented
None Documented
Ibuprofen: 2-4 hours (terminal); requires every 6-8 hour dosing. Famotidine: 2.5-3.5 hours (normal renal function); prolonged to 20 hours or more in severe renal impairment (CrCl < 30 mL/min).
Terminal elimination half-life is 4-6 hours; in severe renal impairment (CrCl <30 mL/min) may extend to 8-12 hours, requiring dose adjustment.
Ibuprofen: ~1% unchanged in urine, 14% as conjugated metabolites, remainder as oxidative metabolites; <1% excreted in feces. Famotidine: 65-70% unchanged in urine, 30-35% metabolized hepatic; <10% fecal.
Primarily renal excretion as unchanged drug (60-70%) and metabolites (20-30%); biliary/fecal elimination accounts for <10%.
Category C
Category C
NSAID/H2 Antagonist Combination
NSAID